Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Early Phase 1

2(40.0%)

N/A

2(40.0%)

Phase 1

1(20.0%)

5Total

Early Phase 1(2)

N/A(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06946745Recruiting

Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer Treated With IBI363 Combination Therapy

Role: lead

NCT05352542Phase 1Terminated

GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma

Role: lead

NCT05940181Not ApplicableUnknown

A Safety and Efficacy Study of XH001 Combined With Sintilimab Injection in Advanced Solid Tumors

Role: lead

NCT05192460Not ApplicableUnknown

Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer, Esophageal Cancer and Liver Cancer

Role: lead

NCT05583201Early Phase 1Recruiting

NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors

Role: lead

NCT05382377Early Phase 1Recruiting

NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors

Role: lead

All 6 trials loaded